Dynamic contrast-enhanced ultrasonography (DCE-US): A new tool for the early evaluation of antiangiogenic treatment

Targeted Oncology

Volumn 5, Issue 1, 2010, Pages 53-58

  Lassau, Nathalie ^a   Chebil, Mohamed ^a   Chami, Linda ^a   Bidault, Sophie ^a   Girard, Elizabeth ^a   Roche, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Contrast agent; Doppler ultrasound; Evaluation of treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; IMATINIB; INTERFERON; PLACEBO; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA;

ANTIANGIOGENIC THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG SCREENING; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE PROCESSING; KIDNEY CARCINOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR VASCULARIZATION; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CIRCULATION; CLINICAL TRIAL (TOPIC); DEVICES; EARLY DIAGNOSIS; FRANCE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; PROGNOSIS; SCINTIGRAPHY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BLOOD CIRCULATION; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; EARLY DETECTION OF CANCER; FRANCE; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION IMAGING; PROGNOSIS; ULTRASONOGRAPHY;

EID: 77952890743     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0136-7     Document Type: Review

References (24)

1. S Rehman GC Jayson 2005 Molecular imaging of antiangiogenic agents Oncologist 10 92 103 10.1634/theoncologist.10-2-92 1:CAS:528: DC%2BD2MXis1Knsbg%3D 15709211 (Pubitemid 40261948)
2. Schwartz L (2005) Imaging in drug discovery: emerging roles and challenges. In: Plenary session, RSNA Program, Chicago, IL, 27 November-2 December 2005, p 35
3. R Benjamin 2006 Response of gastrointestinal stromal tumors to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression J Clin Oncol 24 18S 9506
4. D Cosgrove 2003 Angiogenesis imaging-ultrasound Br J Radiol 76 S43 S49 10.1259/bjr/86364648 15456713 (Pubitemid 39530315)
5. N Lassau S Koscielny P Opolon T De Baere P Peronneau J Leclere A Roche 2001 Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo Invest Radiol 36 50 55 10.1097/00004424-200101000-00007 1:STN:280:DC%2BD3MzitFWktA%3D%3D 11176261 (Pubitemid 32064170)
6. B Escudier N Lassau D Couanet E Angevin F Mesrati S Leborgne, et al. 2002 Phase II trial of thalidomide in renal cell carcinoma Ann Oncol 13 1029 1035 10.1093/annonc/mdf213 1:STN:280:DC%2BD38vitFWgtA%3D%3D 12176780
7. C Greis 2004 Technology overview: Sonovue (Bracco, Milan) Eur Radiol 14 Suppl 8 P11 P15 15700328
8. N Lassau M Lamuraglia D Vanel A Le Cesne L Chami S Jaziri, et al. 2005 Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases Ann Oncol 16 1054 1060 10.1093/annonc/mdi214 1:STN:280: DC%2BD2MzhsFSjtQ%3D%3D 15917312 (Pubitemid 41418305)
9. N Lassau M Lamuraglia L Chami J Leclère S Bonvalot P Terrier, et al. 2006 Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography Am J Roentgenol 187 1267 1273 10.2214/AJR.05.1192 (Pubitemid 44630831)
10. M Lamuraglia B Escudier L Chami B Schwartz J Leclère A Roche N Lassau 2006 To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound Eur J Cancer 42 2472 2479 10.1016/j.ejca.2006.04.023 1:CAS:528:DC%2BD28XhtVagtrbF 16965911 (Pubitemid 44442955)
11. B Escudier N Lassau E Angevin JC Soria L Chami M Lamuraglia E Zafarana, et al. 2007 Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Clin Cancer Res 13 18011809 10.1158/1078-0432.CCR-06-1432 (Pubitemid 46952949)
12. JY Blay B Landi S Bonvalot G Monges I Ray-Coquard F Duffaud, et al. 2005 Recommendations for the management of GIST patients Bull Cancer 92 907 918 16266874
13. Choi H, Faria S, Benjamin R, Podoloff D, Macapinlac H, Charnsangavej C et al (2002) Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIS) with CT and PET: a quantitative analysis. Proceedings of the RSNA Scientific Program, Chicago, p 583
14. U De Giorgi C Aliberti G Benea M Conti M Marangolo 2005 Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors Clin Cancer Res 11 6171 6176 10.1158/1078-0432.CCR-04-2046 16144917 (Pubitemid 41262944)
15. A Le Cesne B Landi S Bonvalot G Monges I Ray-Coquard F Duffaud, et al. 2005 Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales Hepato-Gastro 12 377 389 (Pubitemid 41399580)
16. M Lamuraglia A Le Cesne L Chami S Bonvalot P Terrier T Tursz A Roche N Lassau 2006 Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM) J Clin Oncol 24 18S 9539
17. A Le Cesne B Landi S Bonvalot G Monges I Ray-Coquard F Duffaud B Bui B Nguyen R Bugat JA Chayvialle P Rougier O Bouche F Bonichon N Lassau D Vanel B Nordlinger E Stoeckle P Meeus JM Coindre JY Scoazec JF Emile D Ranchere JY Blay 2006 Recommendations for the management of gastro-intestinal stromal tumors Ann Pathol 26 3 231 234 10.1016/S0242-6498(06)70713-1 17127860
18. WG Kaelin 2002 Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2 673 682 10.1038/nrc885 1:CAS:528:DC%2BD38Xmslamsrg%3D 12209156 (Pubitemid 37328918)
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
20. JC Soria V Lazar N Lassau C Pena C Massard C Robert S Koscielny E Deutsch E Zafarana JP Armand 2007 Sorafenib (S) and dacarbazine (D) combination in patients with advanced malignant solid tumors: phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US) J Clin Oncol 25 18S 3556
21. Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier B (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast -enhanced ultrasonography. Clin Cancer Res 16(4):1216-1225
22. Lassau N, Koscielny S, Chebil M, Chami L, Bendjilali R, Roche A, Escudier B, Le Cesne A, Soria J (2009) Functional imaging using DCE-US: which parameters for the early evaluation of antiangiogenetic therapies? 45th Annual meeting of America Society of Clinical Oncology, Nov 2009, Chicago, IL, USA
23. Lassau N, Lacroix J, Aziza R, Villegrain V, Taieb S, Koscielny S (2009) French Multicentric Prospective Evaluation of Dynamic Contrast-enhanced Ultrasound (DCE-US) for the evaluation of the antiangiogenic treatments. 95th Radiological Society of North America, Nov 2009, Chicago, IL, USA
24. Pellier J, Chevalier J, Koscielny S, Bonastre J, Benatsou B, Lassau N (2009) Methodological Study to Assess the Evolution of the Quality of Dynamic Contrast-enhanced Ultrasound in a Large National Multicentric Study 95th Radiological Society of North America, Nov 2009, Chicago, IL, USA